Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean Wharton

Showing results (51-60 of 98) with videos related to

Pageof 10
Sort By:
The New England Journal of Medicine|September 11, 2025
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or ObesitySean Wharton, Ildiko Lingvay, Pawel Bogdanski, et al.
Obesity Science & Practice|September 3, 2020
Real-world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support programSean Wharton, Christiane L Haase, Elham Kamran, et al.
International Journal of Obesity (2005)|January 19, 2021
Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing dataSean Wharton, Arne Astrup, Lars Endahl, et al.
European Journal of Nutrition|July 10, 2020
Effect of a functional fibre supplement on glycemic control when added to a year-long medically supervised weight management program in adults with type 2 diabetesRaylene A Reimer, Sean Wharton, Tim J Green, et al.
Diabetes, Obesity & Metabolism|July 10, 2023
A model-based approach to predict individual weight loss with semaglutide in people with overweight or obesityAnders Strathe, Deborah B Horn, Malte Selch Larsen, et al.
Obesity (Silver Spring, Md.)|May 8, 2019
Real-World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in CanadaSean Wharton, Aiden Liu, Arash Pakseresht, et al.
Obesity Science & Practice|September 3, 2020
Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real-world effectiveness study in CanadaSean Wharton, Christiane L Haase, Elham Kamran, et al.
Obesity (Silver Spring, Md.)|September 24, 2019
Response to "Liraglutide Effectiveness: Is There a Real-World Clinical Benefit?"Sean Wharton, Aiden Liu, Arash Pakseresht, et al.
Diabetes, Obesity & Metabolism|May 3, 2024
Effect of semaglutide 2.4 mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: Patient-reported outcomes from the STEP 1-4 trialsDomenica Rubino, Jakob B Bjorner, Naveen Rathor, et al.
The Lancet. Diabetes & Endocrinology|September 17, 2025
Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trialIldiko Lingvay, Sara J Bergenheim, John B Buse, et al.
Pageof 10

Showing results (51-60 of 98) with videos related to

Sort By:
Pageof 10
The New England Journal of Medicine|September 11, 2025
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or ObesitySean Wharton, Ildiko Lingvay, Pawel Bogdanski, et al.
Obesity Science & Practice|September 3, 2020
Real-world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support programSean Wharton, Christiane L Haase, Elham Kamran, et al.
International Journal of Obesity (2005)|January 19, 2021
Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing dataSean Wharton, Arne Astrup, Lars Endahl, et al.
European Journal of Nutrition|July 10, 2020
Effect of a functional fibre supplement on glycemic control when added to a year-long medically supervised weight management program in adults with type 2 diabetesRaylene A Reimer, Sean Wharton, Tim J Green, et al.
Diabetes, Obesity & Metabolism|July 10, 2023
A model-based approach to predict individual weight loss with semaglutide in people with overweight or obesityAnders Strathe, Deborah B Horn, Malte Selch Larsen, et al.
Obesity (Silver Spring, Md.)|May 8, 2019
Real-World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in CanadaSean Wharton, Aiden Liu, Arash Pakseresht, et al.
Obesity Science & Practice|September 3, 2020
Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real-world effectiveness study in CanadaSean Wharton, Christiane L Haase, Elham Kamran, et al.
Obesity (Silver Spring, Md.)|September 24, 2019
Response to "Liraglutide Effectiveness: Is There a Real-World Clinical Benefit?"Sean Wharton, Aiden Liu, Arash Pakseresht, et al.
Diabetes, Obesity & Metabolism|May 3, 2024
Effect of semaglutide 2.4 mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: Patient-reported outcomes from the STEP 1-4 trialsDomenica Rubino, Jakob B Bjorner, Naveen Rathor, et al.
The Lancet. Diabetes & Endocrinology|September 17, 2025
Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trialIldiko Lingvay, Sara J Bergenheim, John B Buse, et al.
Pageof 10